CompletedNCT01136772
Comparing Long-Acting Injections for Schizophrenia
About this title
Read the official source — NCT01136772Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Palo Alto and 21 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMarch 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 311
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01136772
- Official title
Show the full official title
A Comparison of Long-Acting Injectable Medications for Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Palo Alto · New Haven · Miami
19 more locations
- Augusta
- Iowa City
- Wichita
- Glen Burnie
- Detroit
- Lansing
- Kansas City
- Omaha
- New York
- Rochester
- Butner
- Chapel Hill
- Durham
- Brecksville
- Philadelphia
- Dallas
- Waco
- Spokane
- Tacoma
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including haloperidol decanoate and paliperidone palmitate.
Who was this study for?
Listed age limits: 18 years to 65 years.
